Penumbra raises FY23 revenue view to $1.04B-$1.06B from $1.0B

Consensus is for FY23 revenue $1.01B. FY23 revenue view represents 23%-25% growth over 2022 revenue of $847.1M. Relative to total revenue guidance range of 23%-25% growth, the company expects growth our vascular business to be slightly above this range and growth in neuro business to be below this range.